Keywords: Eli Lilly, Bristol-Myers Squibb, Lung cancer, Necitumumab, Safety concerns

Eli Lilly, Bristol-Myers Squibb stop enrollment in one Ph III lung cancer trials of necitumumab on blood clot concerns

Article | 03 February 2011

Print This

US drug majors Eli Lilly (NYSE: LLY) and Bristol-Myers Squibb (NYSE: BMY) have stopped enrollment in one of their two ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in